Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Changchun GeneScience Pharmaceutical Co., Ltd.
This is a first-in-human, escalating dose trial of an antibody that inhibits an anti-apoptotic signal in human macrophages. The major aims of the study are to define the safety profile of this new drug, and to determine a recommended dose and schedule for potential additional trials.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient has the willingness to communicate with the investigator, can understand and follow the trial requirements, is willing to participate in the trial, understands and signs a written Informed Consent Form（ICF）, and is willing and able to comply with the visit schedule, administration plan, laboratory examination, and other clinical trial procedures.
Gender: Male or female.
Age 18-70 years old.
Expected survival ≥ 12 weeks.
Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
Patients with advanced solid tumors or NHL by histopathological diagnosis do not have acceptable standard treatment currently.
Adequate organ function per protocol-defined criteria.
You may not be if
Use of protocol-defined prior/concomitant therapy.
Currently receiving or has received an investigational treatment as part of a study within 4 weeks before the first dosing.
History of severe hypersensitivity reaction to study treatments or their excipients.
Known active central nervous system metastases.
History of any active autoimmune disease history, or disease or syndrome requiring treatment with systemic steroids or immunosuppressive medications.
Presence of active infection.
Known additional malignancy that has not been cured in the last 5 years.
Any uncontrolled intercurrent illness or condition that in the judgment of the Investigator may endanger the patient.
Clareo Health | Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma
